$BPSR To Pursue Medical Cannabis License in

New Post Public Reply Private Reply Replies (0) Message Board
BionicBen
142
$BPSR To Pursue Medical Cannabis License in Florida

http://finance.yahoo.com/news/biotech-product...00891.html

Biotech Products Services and Research Inc. to Pursue Medical Cannabis License in Florida

Accesswire AccesswireMarch 2, 2017
MIAMI, FL / ACCESSWIRE / March 2, 2017 / Biotech Products Services and Research Inc. ( OTC PINK: BPSR ) ( "BPSR" or the "Company" ) recently announced in a Form 8-K that it has entered into an agreement pursuant to which the Company intends to aggressively pursue obtaining the required license to operate within the medical cannabis industry in the state of Florida upon the Florida legislature's finalization of the plans for implementing the recently passed Florida Medical Marijuana Legalization Initiative ( "Amendment 2" ). The Company intends to operate this business segment through a newly formed Florida subsidiary, Mint Organics Florida, Inc. ("Mint Organics" ). As mandated by the voters of Florida, BPSR, through Mint Organics, intends to distribute and administer consistent, therapeutic, high quality medical cannabis treatments and products to patients.

Management intends to operate the business with the goal of exceeding the governmental mandates and industry standards, including transparency and controls to assure quality and legitimacy and professionalism of its operations. Mint Organics will be controlled by BPSR, which already has a history of operating within highly regulated and transparent environments as an SEC reporting publicly traded company and operating an existing business involved with research, development, and production of amniotic-based biologics products for the health care industry. Mint Organics also intends to:

Provide the best education and training of associates and the most superior quality products and services to its patients;
Only partner with the most reputable and consistent producers that can deliver certified products that are pesticide and additive free; and
Work closely with health care specialists to ensure that its products meet their specific needs and, more importantly, the needs of their patients.
Peter Taddeo, CEO and co-founder of Mint Organics, is a former senior executive in a number of high technology companies with experience developing and successfully bringing new technologies to market. Taddeo commented, "The field of medical cannabis treatments for painful and debilitating conditions is in its infancy. Our experience in emerging high technology and bio technology makes us uniquely situated to set new standards of access, service, and patient education as this new industry is defined. We plan on working with experienced partners to both develop and bring to market only the highest quality products in a professional environment."

After retiring in late 2012, Taddeo became interested in cutting edge biotechnology, particularly stem cell research in both therapeutic and degenerative/quality of life protocols. That interest led him to research the benefits of medical cannabis and, after viewing a number of medical documentaries about the seemingly miraculous benefits of the product and learning more of the Company's many synergistic objectives, he co-founded Mint Organics with the Company. Taddeo commented, "Mint Organics' name borrows from three critical aspects of what we want to do. Mint is used to describe something as pristine, perfect, and good. Mint is also a shade of green, like cannabis, and finally, Mint is an aromatic herb."

Taddeo sees a bright future for the medical cannabis business and plans to work closely with the state of Florida to realize that future. He believes that the entire state will benefit.

Colorado has reported one billion dollars in total cannabis sales in 2016, generating needed tax revenues to the state to fund important social programs, such as school construction and substance abuse programs. Over 37% of that revenue came from medical cannabis sales. The Company believes that the opportunity for Florida is significantly greater. With nearly four times the population than Colorado, Florida could expect to exceed Colorado's overall sales just in medical cannabis alone. That's several hundred million in new tax revenues for the state.

In addition, Mint Organics plans to create a number of new higher paying specialized jobs, subject to state approval of the dispensary license. Given the Company's aspirations, management believes that there could be up to 100 new jobs created once the Company builds out its dispensary and caregiver network.

For patients suffering from long term chronic afflictions, including chronic pain, cancer treatments, mood disorders, PTSD, seizures and spasticity associated with Multiple Sclerosis ( "MS" ), the benefits versus current treatment protocols are overwhelmingly positive. As the public becomes educated to these benefits, the Company expects that acceptance of cannabis use by patients under physician advice will grow, as well.

Taddeo commented, "We believe medical cannabis provides physicians a new tool to treat these chronic conditions in a way not previously possible and with protocols that do not have the negative side effects of current traditional treatments." Taddeo continued, "In addition, JAMA has reported that in the 23 states that passed medical marijuana laws, death rates from accidental overdoses have declined between 25-30%, and that prescription rates for pain pills were also significantly reduced."

About Biotech Products Services and Research, Inc.

Biotech Products Services and Research, Inc. ( "Company" ), and its subsidiaries, are suppliers of products and services used in the growing health care field of regenerative medicine.

The Company's strategy is to be a leading supplier of newly designed advanced biologically processed cellular and tissue based products and services used in the growing health care field of regenerative medicine.

CAUTIONARY COMMENT REGARDING FORWARD-LOOKING STATEMENTS

The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Biotech Products Services & Research, Inc., and its subsidiaries, including but not limited to, Mint Organics, Inc.'s plans and expectations. In this press release and related comments by Company management, words like "intends," "expect," "anticipate," "estimate," "goal," and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.

Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation, and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Other information can be obtained at www.bpsrhealth.com. The contents of the Company's website are not incorporated by reference in this Press Release.

CONTACT:

Biotech Products Services and Research, Inc.
4045 Sheridan Ave., Suite 239
Miami Beach, FL 33140
Website: http://www.bpsrhealth.com
Phone: (888) 963-7881
Email: info@bpsrhealth.com

SOURCE: Biotech Products Services and Research Inc.
Disclaimer:
There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator.
Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.
There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in all and any posts.
My posts are NOT investment advice. I am not paid to post.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 33

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 32

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 25

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 26

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 32

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 23

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 15

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

TKO Group Launches Major Share Buyback and Dividend Initiative

Updated Category News Views 669

TKO Group Announces Strategic Financial Moves TKO Group Holdings, Inc. (NYSE: TKO) has recently made headlines with its announcement of a remarkable share repurchase program amounting to $2 billion. Alongside this significant initiative, the company is introducing a quarterly cash dividend that is projected to reach $75 million. These strategic financial maneuvers reflect...

Continue Reading
An Insightful Look at Warner Bros. Discovery's Declining Short Interest

Updated Category News Views 64

Understanding Warner Bros. Discovery's Short Interest Trends Warner Bros. Discovery (WBD) has seen a noteworthy drop in its short percent of float, falling by 11.22% since the last report. Currently, the company reports that there are 101.75 million shares sold short, representing about 4.67% of all available shares for trading. Interestingly, based on the current trading...

Continue Reading
Avobis Bio Advances Clinical Trials for Innovative Therapy Solutions

Updated Category News Views 185

Avobis Bio Unveils Breakthrough in Clinical Trial for AVB-114 Avobis Bio LLC, a pioneering company focused on developing innovative implantable cell therapies, has made a remarkable stride by completing the primary analysis of the STOMP-II randomized clinical trial targeting Crohn's perianal fistulas. This analysis brings with it exciting prospects for FDA interaction and...

Continue Reading
Innovative Bait Accessory Enhances Fishing Experience

Updated Category News Views 239

Revolutionizing Fishing with a New Bait Accessory Fishing is more than just a hobby; it's a passion for many outdoor enthusiasts. That's why the recent invention of the E Z BAIT accessory is creating waves in the angling community. Designed for all fishing lovers, it aims to keep your bait right where you need it without missing a beat. Convenience at Your Fingertips...

Continue Reading
Oncoinvent ASA: Advancing Cancer Therapies with Financial Focus

Updated Category News Views 158

Oncoinvent ASA's Periodic Performance Highlights Oncoinvent is making strides in the oncology sector, particularly with its Phase 2 trial for ovarian cancer. This clinical-stage biotechnology company is diligently focusing on expanding its research scope while ensuring sound financial management practices. Their primary product, Radspherin®, is a radiopharmaceutical...

Continue Reading